Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | HTR2C | P28335 | 2/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 3/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7235162 | 0.85 | KMT2A (0.55) | ESR1HTR2AHTR2CHTR2BACHE | |
| Hydrochloric Acid SCHEMBL7235158 | 0.85 | KMT2A (0.57) | ESR1HTR2AHTR2CHTR2BACHE | |
| Hydrochloric Acid SCHEMBL7235165 | 0.85 | KMT2A (0.57) | ESR1HTR2AHTR2CHTR2BACHE | |
| SCHEMBL6203630 | 0.79 | PARP1 (0.52) | ESR1ACHEHRH3KDRMAOB | |
| Hydrochloric Acid SCHEMBL7227956 | 0.78 | PARP1 (0.52) | ESR1ACHEHRH3 | |
| SCHEMBL6203624 | 0.78 | TLR8 (0.53) | ESR1ACHEHRH3MAOB | |
| Hydrochloric Acid SCHEMBL7226820 | 0.77 | TLR8 (0.52) | ESR1ACHE | |
| SCHEMBL1793194 | 0.77 | SIGMAR1 (0.57) | ACHEHRH3MAOB | |
| SCHEMBL1793752 | 0.76 | KDM4E (0.57) | HRH3 | |
| SCHEMBL1795765 | 0.75 | SIGMAR1 (0.56) | HRH3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1266887-B1 | Indenoindoline derivatives, their process of preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2005-08-17 | — | — | EP | disclosed |
| US-6627650-B2 | An isomer thereof, or an addition salt thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful as anti- cancer agents. | LES LABORATOIRES SERVIER (FR) | 2003-09-30 | — | — | US | disclosed |
| US-20030125369-A1 | Indeno(1,2-b)indole oximes or indeno(1,2-b) indole hydrazones used as anticancer agent | LES LABORATOIRES SERVIER (FR) | 2003-07-03 | — | — | US | disclosed |
| EP-1266887-A2 | Indenoindoline derivatives, their process of preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2002-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125369-A1 | Indeno(1,2-b)indole oximes or indeno(1,2-b) indole hydrazones used as anticancer agent | IDO1, IDO2, AHR | ESR1 1495/4885HTR2A 122/4885HTR2C 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.